Mitoxantrone in the treatment of metastatic transitional cell carcinoma of the prostate. A case report

Am J Clin Oncol. 1997 Aug;20(4):381-2. doi: 10.1097/00000421-199708000-00012.

Abstract

A 61-year-old man with pulmonary and bone metastases from a primary transitional cell carcinoma of the prostate (TCCP) refractory to MVAC was treated with mitoxantrone 16 mg/m2 i.v. at 3-week intervals. With this, he experienced an objective partial remission lasting 5 months and a significant decrease in cancer-related symptoms. Mitoxantrone deserves further evaluation in this rare disease.

Publication types

  • Case Reports

MeSH terms

  • Antibiotics, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / secondary
  • Carcinoma, Transitional Cell / drug therapy
  • Carcinoma, Transitional Cell / secondary*
  • Cisplatin / administration & dosage
  • Disease Progression
  • Doxorubicin / administration & dosage
  • Fatal Outcome
  • Follow-Up Studies
  • Humans
  • Injections, Intravenous
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Mitoxantrone / therapeutic use*
  • Prostatic Neoplasms / drug therapy*
  • Remission Induction
  • Vinblastine / administration & dosage

Substances

  • Antibiotics, Antineoplastic
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Vinblastine
  • Doxorubicin
  • Mitoxantrone
  • Cisplatin
  • Methotrexate

Supplementary concepts

  • M-VAC protocol